RBC Capital Remains Bullish on PTC Therapeutics (PTCT) Following Waylivra CRL
Tweet Send to a Friend
RBC Capital analyst, Brian Abrahams, reiterated an Outperform rating and $51.00 price target on PTC Therapeutics (NASDAQ: PTCT) following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
